Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
Phase 3b Study Designed to Further Evaluate ALKS 5461’s Potential Benefits on Mood Domains Regulated by Endogenous Opioid Modulation Company Reiterates Plans to Submit New Drug Application to FDA by Year-End 2017 DUBLIN–(BUSINESS WIRE)–Jun. 12, 2017– Alkermes plc (NASDAQ: ALKS) today announced the initiation of study 217, a phase 3b trial of ALKS 5461, a […]